- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05164055
Avalglucosidase Alfa French Access efter rättegång för deltagare med Pompes sjukdom (PTA Avalglucosidase)
En fransk multicenter fas 4 öppen utvidgningsstudie av långsiktig säkerhet och effekt hos patienter med Pompes sjukdom som tidigare deltagit i Avalglucosidas Development Studies i Frankrike
Denna långsiktiga öppna säkerhets- och effektstudie är avsedd att följa upp och ge tillgång till enzymersättningsterapi (ERT) med avalglucosidas alfa efter studien till patienter med Pompes sjukdom i Frankrike som har genomfört studie EFC14028, LTS13769 eller ACT14132 , från marknadsgodkännande tills återbetalning av avalglucosidase alfa i Frankrike eller till maj 2023, beroende på vad som inträffar först.
- Studiebesöksfrekvens: varannan vecka
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 4
Kontakter och platser
Studieorter
-
-
-
Bordeaux, Frankrike, 33000
- Investigational Site Number : 2500004
-
Brest, Frankrike, 29609
- Investigational Site Number : 2500005
-
Clermont-Ferrand, Frankrike, 63000
- Investigational Site Number : 2500008
-
Lille, Frankrike, 59037
- Investigational Site Number : 2500009
-
Lyon, Frankrike, 69003
- Investigational Site Number : 2500003
-
Marseille, Frankrike, 13385
- Investigational Site Number : 2500001
-
Nantes, Frankrike, 44093
- Investigational Site Number : 2500006
-
Nice, Frankrike, 06200
- Investigational Site Number : 2500007
-
Paris, Frankrike, 75013
- Investigational Site Number : 2500002
-
Paris, Frankrike, 75015
- Investigational Site Number : 2500010
-
Tours, Frankrike, 37044
- Investigational Site Number : 2500011
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Beskrivning
Inklusionskriterier:
- Patient med Pompes sjukdom som tidigare har genomfört studie EFC14028, LTS13769 eller ACT14132 av avalglucosidas alfa-studier i Frankrike.
- Patienten och/eller dennes förälder/vårdnadshavare är villig och kan ge ett undertecknat informerat samtycke, och patienten, om <18 år, är villig att ge samtycke om han bedöms kunna göra det.
- Patienten (och patientens vårdnadshavare om patienten är <18 år) måste ha förmågan att följa det kliniska protokollet.
- Patienten, om hon är kvinna och i fertil ålder, måste ha ett negativt graviditetstestresultat [urin beta-humant koriongonadotropin (β-HCG)] vid inskrivningen.
- Sexuellt aktiva kvinnliga patienter i fertil ålder och manliga patienter måste utöva sann abstinens i linje med sin föredragna och vanliga livsstil eller att använda två acceptabla effektiva preventivmetoder.
Exklusions kriterier:
- Patient med livshotande överkänslighet (anafylaktisk reaktion) mot något av avalglucosidase alfas hjälpämnen.
- Patienten deltar samtidigt i en annan klinisk studie av prövningsbehandling.
- Patienten har kliniskt signifikant organisk sjukdom (med undantag för symtom relaterade till Pompes sjukdom), inklusive kliniskt signifikanta kardiovaskulära, hepatobiliära, lung-, neurologiska eller njursjukdomar, eller annat medicinskt tillstånd, allvarlig interkurrent sjukdom eller förmildrande omständighet som, i utredarens åsikt, utesluter deltagande i studien eller minskar potentiellt överlevnaden.
Ovanstående information är inte avsedd att innehålla alla överväganden som är relevanta för en patients potentiella deltagande i en klinisk prövning.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Avalglucosidas alfa
Administreras intravenöst varannan vecka
|
Läkemedelsform: Sterilt lyofiliserat pulver Administreringssätt: intravenös (IV) infusion
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Number of participants with adverse events (AE), treatment-emergent adverse events (TEAE), including infusion associated reactions (IAR) and death
Tidsram: From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months
|
From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Assessment of six-minute walk test (distance in meters and % predicted value) for late-onset Pompe disease (LOPD) and infantile-onset Pompe disease (IOPD) participants
Tidsram: From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
|
The primary measurement is the distance in meters walked by the participant on a flat, hard surface in 6 minutes.
The distance walked in meters will be recorded and the corresponding percent predicted value will be calculated.
The greater the distance (that a participant could walk in 6 minutes), the greater the endurance.
|
From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
|
|
Assessment of quick motor function test (QMFT) for LOPD participants
Tidsram: From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
|
The QMFT is an observer administered test to evaluate changes in motor function.
QMFT comprises of 16 items specifically difficult for participants with Pompe disease.
Each item is scored separately on a 5-point ordinal scale (ranged from 0 to 4, higher score indicated better outcome).
Total QMFT score is obtained by adding the scores of all items and ranged from 0 (unable to perform motor function tests) to 64 (normal muscle function), higher score represented better outcome.
|
From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
|
|
Pulmonary function tests (forced vital capacity [FVC] (% predicted), maximum expiratory pressure/maximum inspiratory pressure) in upright and supine positions for LOPD and IOPD participants
Tidsram: From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
|
FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC is the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position, also tested in supine position. Percent of predicted FVC = (actual FVC measurement)/(predicted value of FVC) * 100. Maximum Inspiratory Pressure (MIP) is a quick and non-invasive test to measure strength of inspiratory muscles, primarily diaphragm, and allows for assessment of ventilatory failure, restrictive lung disease and respiratory muscle strength. MIP refers to how much air pressure force an individual creates by inhaling through the mouth as hard as possible. Maximum Expiratory Pressure (MEP) is a quick and non-invasive test to measure strength of expiratory muscles, primarily diaphragm, and allows for assessment of ventilatory failure, restrictive lung disease and respiratory muscle strength. MEP is the greater pressure generated during maximal expiration. |
From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
|
|
Quality of life evaluation: 12-item short form health survey (SF-12) for LOPD participants
Tidsram: From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
|
SF-12, a 12 item-questionnaire, used to assess health-related quality of life in participants aged >=18 years at screening/baseline.
SF-12 consisted of 12 items, which were categorized into eight domains (subscales) of functioning and well-being: physical functioning, role-physical, role emotional, mental health, bodily pain, general health, vitality and social functioning, with each domain score ranged from 0 (poor health) to 100 (better health), higher scores indicated good health condition.
These eight domains were further summarized into 2 summary scores, physical component summary (PCS) and mental component summary (MCS).
The score range for each of these 2 summary scores was from 0 (poor health) to 100 (better health), higher scores indicated a better health-related quality of life.
|
From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
|
|
Quality of life evaluation: Pompe Disease Symptom Scale (PDSS) for LOPD participants
Tidsram: From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
|
The 24-hour recall PDSS (V1.1) is a self-administered questionnaires specifically designed to capture the symptoms impacts relevant to patients with LOPD.
The PDSS includes 12 questions with responses on a scale from 0 (none) to 10 (as bad as I can imagine) The data from PDSS scale will be analyzed separately and as a composite with PDIS scale.
|
From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
|
|
Quality of life evaluation: Pompe Disease Impact Scale (PDIS) for LOPD participants
Tidsram: From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
|
The 24-hour recall PDIS (V1.2) is a self-administered questionnaires specifically designed to capture disease impacts relevant to patients with LOPD.
The PDIS includes 15 questions with varying scales implemented depending on question type.
The data from PDIS scale will be analyzed separately and as a composite with PDSS scale.
|
From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
|
|
Pompe Pediatric Evaluation of Disability Inventory (Pompe-PEDI) score for IOPD participants
Tidsram: From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
|
The Pompe-PEDI consists of a Functional Skills Scale and a Caregiver Assistance Scale.
Both scales have 3 domains: self-care; mobility; and social function.
The Mobility Domain was selected to measure change in mobility secondary to changes in muscle strength.
The domain consists of 160 mobility items.
|
From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
|
|
PedsQL score for IOPD participants
Tidsram: From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
|
The 23item PedsQL Generic Core Scale encompasses 4 subscales including physical, emotional, school, and social functionings. Scores are transformed to a 0-100 scale, higher scores indicate better HRQOL. Infant scale will not be used since this is a scale for up to 24 months of age and patients are older now than that. |
From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
|
|
Left Ventricular Mass Index (LVMI) Z-score in IOPD participants
Tidsram: From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
|
Left Ventricular Mass Index (LVMI) equivalent to mean age specific LVMI plus 2 standard deviations.
|
From study enrolment to the final study visit/telephone contact, up to 4 years and 11 months (at enrolment and every 6 months)
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Clinical Sciences & Operations, Sanofi
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Hjärnsjukdomar
- Sjukdomar i centrala nervsystemet
- Sjukdomar i nervsystemet
- Metabolism, medfödda fel
- Genetiska sjukdomar, medfödda
- Metaboliska sjukdomar
- Kolhydratmetabolism, medfödda fel
- Lysosomala lagringssjukdomar
- Hjärnsjukdomar, metabola, medfödda
- Hjärnsjukdomar, metaboliska
- Lysosomala lagringssjukdomar, nervsystemet
- Glykogenlagringssjukdom
- Medfödda, ärftliga och neonatala sjukdomar och abnormiteter
- Närings- och metabola sjukdomar
- Glykogenlagringssjukdom typ II
Andra studie-ID-nummer
- PTA17333
- 2021-002590-26 (EudraCT-nummer)
- U1111-1266-5434 (Registeridentifierare: ICTRP)
- 2024-514773-22 (Registeridentifierare: CTIS)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .